Share your clinical perspective and help shape future understanding of neurological care.
Ambit is conducting a market research advisory board with physicians to better understand how clinicians interpret emerging clinical data, evaluate treatment options, and make real-world decisions for patients with developmental and epileptic encephalopathies (DEE), including SCN2A and SCN8A.
We are inviting a small group of qualified physicians to participate in a moderated, in-person discussion alongside peers.
The advisory board consists of a single, full-day session with no follow-up or pre-work required. The session will occur on a weekday based on availability of other qualified participants.
The session will cover clinical scenarios and emerging data, including anonymized cases and relevant literature to support discussion.
Discussion will be moderated by a professional facilitator and will include peer-to-peer exchange among healthcare providers, incorporating perspectives from practicing clinicians.
Sessions take place in Chicago, Dallas, and New York, with dates available between May and June.
An honorarium will be provided in accordance with fair market value and Sunshine Act reporting requirements.
Travel expenses will be covered, including airfare, local transportation, and hotel accommodations in line with policy.
A short screener confirms eligibility in about 3–5 minutes.
This activity is non-promotional and is not intended to influence clinical decision-making. Participation is for research purposes only.
All responses will be kept confidential and reported only in aggregated, de-identified form.
The sponsor's identity will be disclosed to qualified participants following completion of the eligibility screener.
Participation may be subject to eligibility criteria and applicable Sunshine Act reporting requirements.
Please complete the short screener below. It will take approximately three to five minutes.
